Recurrent gastrointestinal stromal sarcomas.

[1]  M. Heslin,et al.  Primary Gastrointestinal Sarcomas , 2000, The American surgeon.

[2]  G. Rosen,et al.  Surgical Resection and Intraperitoneal Chemotherapy for Recurrent Abdominal Sarcomas , 1999, Annals of Surgical Oncology.

[3]  J. Lasota,et al.  Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. , 1999, The American journal of pathology.

[4]  A. Kovatich,et al.  CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[5]  P. Sugarbaker.  Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. , 1998, Seminars in surgical oncology.

[6]  P. Sugarbaker,et al.  Analysis of morbidity and mortality in 60 patients with peritoneal carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy , 1996, Cancer.

[7]  J. Jassem,et al.  Sarcoma of the uterus , 1956, Archives of Gynecology and Obstetrics.

[8]  L. Ellis,et al.  Gastrointestinal leiomyosarcoma metastatic to the liver. Durable tumor regression by hepatic chemoembolization infusion with cisplatin and vinblastine , 1995, Cancer.

[9]  D. Coit,et al.  Hepatic Metastases from Soft‐Tissue Sarcoma , 1995, Annals of surgery.

[10]  P. Sugarbaker,et al.  Morbidity and mortality of cytoreductive surgery and intraperitoneal chemotherapy. , 1993, Surgery.

[11]  P. Sugarbaker,et al.  Sarcomas Involving the Abdominal and Pelvic Cavity , 1993, Tumori.

[12]  L. Blumenson,et al.  Surgery for disseminated abdominal sarcoma. , 1992, American journal of surgery.

[13]  R. Pollock,et al.  Prognostic implications of patterns of failure for gastrointestinal leiomyosarcomas , 1992, Cancer.

[14]  E. Atkinson,et al.  Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. , 1992, Annals of surgery.

[15]  C. Compton,et al.  Sarcomas of the gastrointestinal tract. Separation into favorable and unfavorable prognostic groups by mitotic count. , 1991, Annals of surgery.

[16]  S. Wallace,et al.  Regression of hepatic metastases from gastrointestinal leiomyosarcoma after hepatic arterial chemoembolization , 1991, Cancer.

[17]  S. Rubin,et al.  Phase II trial of intraperitoneal mitoxantrone in the management of refractory ovarian cancer. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  A. Elias,et al.  Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  D. Alberts,et al.  Phase I clinical and pharmacokinetic study of mitoxantrone given to patients by intraperitoneal administration. , 1988, Cancer research.

[20]  I. Smith,et al.  Mitoxantrone (novantrone): a review of experimental and early clinical studies. , 1983, Cancer treatment reviews.

[21]  O. Beahrs,et al.  Leiomyosarcoma of the small and large bowel , 1978, Cancer.

[22]  Giarratano Rc,et al.  Sarcomas of the uterus. , 1971 .